Deals Of The Week: Novartis/Genoptix, Amgen/BioVex, Ligand/Cydex
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
Pfizer doesn't exactly do things by halves. Two years after pulling off the sector's biggest merger, it now appears to be carrying out the largest-scale – and most ambitious – academic tie-up yet.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.